Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04804033 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,753
- Enrollment target
NCT04804033 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,753 participants.
The verdict
NCT04804033, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,753 participants
- Enrollment target
Study Summary
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Interventions
- DRUG Placebo
- DRUG BHV-3500 (zavegepant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,753 participants |
| Start Date | 2021-03-26 |
| Est. Completion | 2024-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04804033
The ClinicalTrials.gov registry entry for NCT04804033 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1,753 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04804033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04804033 about?
NCT04804033 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention". The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
What is the current status of trial NCT04804033?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,753 participants. The study started on 2021-03-26. Estimated completion is 2024-03-21.
What interventions are being tested in trial NCT04804033?
The interventions under investigation include: Placebo (DRUG), BHV-3500 (zavegepant) (DRUG).
Who is sponsoring clinical trial NCT04804033?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.